Pressure to make new Lundbeck drug a success rests on Peter Anastasiou
The head of Lundbeck in the USA, Peter Anastasiou, has prepared the US organization for the launch of migraine drug Vyepti at record speed. It is Lundbeck's first new launch since 2015 - and it is a big task to bear.
BY ELIZABETH MØNSTED JOHANSEN, TRANSLATED BY CATHERINE BRETT
Log in to read our articles
Welcome to MedWatch. A part of our content is exclusive and reserved for our users.